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ABSTRACT
A roundtable to discuss the measurement of folate status bio-
markers in NHANES took place in July 2010. NHANES has mea-
sured serum folate since 1974 and red blood cell (RBC) folate
since 1978 with the use of several different measurement proce-
dures. Data on serum 5-methyltetrahydrofolate (5MTHF) and folic
acid (FA) concentrations in persons aged 6 0ya r ea v a i l a b l ei n
NHANES 1999–2002. The roundtable reviewed data that showed
that folate concentrations from the Bio-Rad Quantaphase II procedure
(Bio-Rad Laboratories, Hercules, CA; used in NHANES 1991–1994
and NHANES 1999–2006) were, on average, 29% lower for serum
and 45% lower for RBC than were those from the microbiological
assay (MA), which was used in NHANES 2007–2010. Round-
table experts agreed that these differences required a data adjust-
ment for time-trend analyses. The roundtable reviewed the
possible use of an isotope-dilution liquid chromatography–tan-
dem mass spectrometry (LC-MS/MS) measurement procedure for
future NHANES and agreed that the close agreement between the
MA and LC-MS/MS results for serum folate supported conversion
to the LC-MS/MS procedure. However, for RBC folate, the MA
gave 25% higher concentrations than did the LC-MS/MS pro-
cedure. The roundtable agreed that the use of the LC-MS/MS pro-
cedure to measure RBC folate is premature at this time. The
roundtable reviewed the reference materials available or under devel-
opment at the National Institute of Standards and Technology and
recognized the challenges related to, and the scientiﬁc need for, these
materials. They noted the need for a commutability study for the
available reference materials for serum 5MTHF and FA. Am J
Clin Nutr 2011;94(suppl):303S–12S.
INTRODUCTION
TheNHANESprogramisavaluablesourceofdataontheUS
population’s nutritional and health status. NHANES I (1974–
1975) was the ﬁrst NHANES to measure serum folate con-
centrations (1). NHANES II began measuring red blood cell
(RBC) folate concentrations in 1978–1980. NHANES has con-
tinued the measurement of both biomarkers through 2010 and
will measure them in 2011–2012.
The US Food and Drug Administration partnered with the
National Center for Health Statistics of the Centers for Disease
Control and Prevention to convene expert panels in 1983–1984
and 1994 to review folate biomarker data from NHANES II
(1976–1980)andNHANESIII(1988–1994)(2,3).Interestin
the assessment of folate status increased with the 1996 imple-
mentation of folic acid (FA) fortiﬁcation of cereal grains in the
United States (4). NHANES data documented substantial ele-
vations in serum and RBC folate concentrations after fortiﬁcation
(1, 5, 6). In the postfortiﬁcation era, public health concerns have
shifted from inadequate intakes to potential adverse effects as-
sociated with excessive FA intakes from fortiﬁed foods and di-
etary supplements (7–10).
The National Center for Health Statistics and the Ofﬁce of
Dietary Supplements of the National Institutes of Health con-
vened a roundtable panel on 15–16 July 2010, in Rockville, MD,
to review measurement issues for folate and vitamin B-12 status
biomarkers in NHANES that have arisen since the 1994 expert
1 From the Ofﬁce of Dietary Supplements (EAY, RLB, CS, PMC, MFP),
Genome Technology Branch, National Human Genome Research Institute
(LCB), and Eunice Kennedy Shriver National Institute of Child Health and
Human Development (JLM), National Institutes of Health, Bethesda, MD;
National Center for Environmental Health, Centers for Disease Control and
Prevention, Atlanta, GA (CMP, ZF); the Analytical Chemistry Division,
National Institute of Standards and Technology, Gaithersburg, MD (KWP);
National Center for Health Statistics, Centers for Disease Control and Pre-
vention, Hyattsville, MD (DAL, LRC, CLJ); the Haematology Department,
United Kingdom National External Quality Assessment Service, Sutton
Coldﬁeld, United Kingdom (SB); the Department of Pathology, Stony Brook
University Medical Center, Stony Brook, NY (JLB); the Department of
Medicine, New York Methodist Hospital, Brooklyn, NY, and Weill Medical
College, Cornell University, New York, NY (RC); the Department of Pre-
ventive Medicine and Epidemiology, Loyola University Chicago Stritch
School of Medicine, Maywood, IL (RAD-A); the Department of Laboratory
Medicine and Pathology, University of Minnesota, Minneapolis, MN (JHE);
the Department of Medical Pathology and Laboratory Medicine and Medi-
cine, University of California Davis, Sacramento, CA (RG); the Food Sci-
ence and Human Nutrition Department, University of Florida, Gainesville,
FL (JFG); the Departments of Laboratory Medicine and Medicine, Univer-
sity of Washington, Seattle, WA (ANH); the Department of Molecular Med-
icine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve
University, and the Department of Cell Biology, Lerner Research Institute,
Cleveland Clinic, Cleveland, OH (DWJ); Jean Mayer US Department of
Agriculture Human Nutrition Research Center on Aging, Tufts University,
Boston, MA (PFJ, JS); the Department of Clinical Medicine, School of
Medicine, Trinity College, Dublin, Ireland (AMM); the Department of Bio-
statistics, Boston University School of Public Health, Boston, MA (JM); the
Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus,
Denmark (EN); the Center for Food Safety and Applied Nutrition, Food and
Drug Administration, College Park, MD (JIR); the Department of Nutritional
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review of 1) the quality of the folate-related measurement pro-
cedures that NHANES has used or that are available for future
surveys, 2) the quality of the reference measurement procedures
and reference materials currently available or under develop-
ment, and 3) public health considerations for the choice of which,
if any, folate-related biomarkers to measure in future NHANES.
Other articles in this supplement provide background information
on biomarker measurement and use and the roundtable’s review
of vitamin B-12 status biomarkers (1, 11–16). In a separate, in-
troductory article, we describe how the individual articles within
this supplement packet ﬁt within the overall roundtable process
(17). We also describe the relevance of the roundtable review and
dialogue to clinical and research settings outside the NHANES
context.
THE ROUNDTABLE
The roundtable panel included 23 experts in folate and vitamin
B-12 assessment, epidemiology, clinical laboratory science, and
biostatistics. The roundtable also had 10 scientists from govern-
ment agencies that conduct and fund folate biomarker mea-
surements in NHANES and develop relevant reference methods
and materials.
The roundtable reviewed 3 biomarkers of folate status that
NHANES has used: serum and RBC folate and total homo-
cysteine. Because of the increasing interest in folate vitamer
measurement (8, 10, 18, 19), the panel also considered these
biomarkers’ usefulness for future NHANES. Because vitamin
B-12 status is the predominant nutrient determinant of high total
homocysteine concentrations among the US elderly (13, 20–22),
the article on vitamin B-12 status measurements in NHANES
describes the roundtable’s review of total homocysteine mea-
surements in NHANES (16).
The roundtable reviewed folate-related measurement quality
and public health issues in the context of the NHANES mission
and capabilities. Roundtable members did not consider broader
research and clinical application issues or the differences between
themeasurementproceduresthatresearch,clinical,andcommercial
laboratories use. The roundtable did identify and discuss the sci-
entiﬁc issues involved in the decision as to whether to include
folate-related biomarkers in NHANES, but did not make policy
recommendations. When we present serum and RBC folate data in
thisarticle,weexpressvaluesinnmol/L(1.0ng/mL=2.266nmol/L).
MEASUREMENT OF FOLATE BIOMARKERS IN NHANES
Barry Shane (12) described serum and RBC folate concen-
tration measurement. The measurement of folate is complicated
because biological (vitamin) activity is associated with many
folate forms that vary by oxidation state of the pterin ring, one-
carbon substitutes, and glutamate chain length. These multiple
formscanalsoproducemanyfolatebreakdownproductsthatlack
biological activity but can complicate measurement.
Historically, nutrition scientists have favored the microbio-
logical assay (MA) because, with appropriate sample processing,
it measures all biologically active folate species but not degra-
dationproductsthatlackbiologicalactivity(12).Inthe1970sand
1980s, commercial kits that used protein-binding procedures
became popular because of their ease of use and high throughput.
Recently, liquid chromatography–tandem mass spectrometry (LC-
MS/MS) measurement procedures have gained interest because of
their potential to quantify folate vitamers. Because NHANES has
used the MA and competitive radio protein-binding measurement
procedures and is considering the use of LC-MS/MS in the future,
the roundtable reviewed the use of these 3 procedures in NHANES.
NHANES began the measurement of folate biomarkers in
1974–1975 with the use of an MA (Table 1); however, the
roundtable focused primarily on NHANES measures after the
1991 introduction of the Bio-Rad Quantaphase II competitive
protein-binding measurement procedure (Bio-Rad Laboratories,
Hercules, CA). Previous expert panels have reviewed the mea-
surement quality and comparability issues associated with MA in
1974–1975 and 1976–1978, the conversion to the Bio-Rad I kit in
1978, and the conversion to the Bio-Rad II kit in 1991 (2, 3).
The Bio-Rad measurement procedure (NHANES
1991–1994 and 1999–2006)
Christine Pfeiffer of the Centers for Disease Control and
Prevention’s National Center for Environmental Health (NCEH)
described the use of the Bio-Rad measurement procedure in
NHANES. Details on the laboratory procedures and quality
control results are available elsewhere (23–27). The Bio-Rad
procedure is precise. The Bio-Rad Quantaphase II (1991–1994
and 1999–2006) showed CVs of 4–8% for serum folate across
a range of ’2–30 nmol/L, and 4–6% for RBC folate across
a range of ’75–1100 nmol/L (5, 23–27). In surveys that have
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RBC folate have been stable and reproducible (23–27).
However, the Bio-Rad procedure has had accuracy problems.
TheNCEHcompareditsBio-Radresultswiththeassignedvalues
of the reference materials that became available in 2006. The
National Institute of Standards and Technology (NIST) standard
reference material (SRM) 1955 has information values for 3
levels of serum total folate concentrations based on the LC-MS/
MS, MA, and Bio-Rad measurement procedures (28). Compared
with the SRM 1955 LC-MS/MS–derived values for total folate,
the NCEH Bio-Rad results were ’25% lower than the low and
medium SRM 1955 materials (level 1 at 6.0 nmol/L and level 2
at 13.1 nmol/L) and ’40% lower than the high concentration
material (level 3 at 41 nmol/L). NCEH observed similar dif-
ferences between the MA-derived SRM 1955 information values
and its NCEH Bio-Rad–based results. In the National Institute
for Biological Standards and Control (NIBSC; http://www.nibsc.
ac.uk/) reference materials, the NCEH Bio-Rad results were
’10% lower for serum (NIBSC 03/178 with an assigned con-
centration of 12.1 nmol/L by LC-MS/MS) (29) and ’45% lower
for whole blood (NIBSC 95/528 with an assigned concentration
of 29.4 nmol/L by consensus value that several laboratories
measured with the use of MA and radioimmunoassay proce-
dures) (30). In the College of American Pathologists (http://
www.cap.org/apps/cap.portal) Ligand Survey, NCEH’s Bio-Rad
results were ’40% lower than those of the All Laboratory
Trimmed Mean for serum and ’50% lower for RBC folate. The
All Laboratory Trimmed Mean is composed of results from all
participating measurement procedures and, as a result, can ﬂuc-
tuate as different measurement procedures become part of the
proﬁciency testing scheme. Because the Bio-Rad measurement
procedure did not have enough respondents for the summary re-
port to include as a peer group, the NCEH results could not be
compared with the method-speciﬁc peer group results.
A likely contributor to the lower serum total folate concen-
trations with the Bio-Rad procedure is underrecovery of
5-methyltetrahydrofolic acid (5MTHF), the predominant folate
species in serum and RBC (31, 32). In fortiﬁcation and recovery
studies with the Bio-Rad procedure, NCEH observed 5MTHF
recoveries of ’60% for serum and ’50% for whole blood
(Table 2). Although FA recovery was almost complete, the
measured recovery of other minor folate species was much lower
or higher than desirable. The UK National External Quality As-
sessment Service program obtained similar results in an indepen-
dent spiking recovery experiment for 5MTHF and FA (33).
The roundtable noted that unlike the MA that detects all bio-
logically active folate species equally, the competitive binding
procedures bind different folate species with different afﬁnities.
This is problematic not only because it adversely affects accuracy
butalsobecausetherelativeone-carbondistributionoffolateforms
inRBCscandifferbygenotypebetweenindividuals.Theonlyway
to correct these binding afﬁnity differences is through the use of
a separate standard for each folate species in the sample. Manu-
facturers sometimes change commercial kit standards in ways that
users cannot control or know of, matrix effects can affect results,
and kits’ limited analytic range may be inadequate for the high
serum and RBC folateconcentrations that are typicalinthe post-FA
fortiﬁcation era.
Microbiological measurement procedure (NHANES
2007–2010)
Characteristics of the microbiological measurement procedure
After the manufacturer discontinued production of the Bio-
Rad kits in 2006, NHANES began to use the MA in 2007 (Table
1). Pfeiffer reported on a study in which 3 laboratories analyzed
samples from a one-third NHANES subsample (n = 2645 for
serum and 2613 for RBC) to ascertain the comparability of re-
sults. Serum folate geometric means (6SE) were 39.5 6 0.42,
59.2 6 0.68, and 47.7 6 0.53 nmol/L; the values for RBC folate
that corresponded were 1118 6 8.7, 1384 6 13.9, and 1377 6
10.9 nmol/L. Pearson’s correlation coefﬁcients (r)w h e n2
laboratories were compared at a time were 0.801–0.951 for se-
rum and 0.651–0.917 for RBC folate. Bland-Altman relative bias
results when 2 laboratories were compared at a time were 19–39%
forserumand1–21%forRBCfolate.Themainproceduraldifferences
TABLE 1
Measurement of serum and red blood cell folate in NHANES
1
Survey date Measurement procedure Matrix Laboratory Population age
1974–1975 Microbiological Serum NCEH 25–74 y
1976–1978 Microbiological Serum NCEH 6 mo–74 y, subset
1978–1980 Bio-Rad QP I Serum, WB lysate NCEH 6 mo–74 y, subset
1988–1991 Bio-Rad QP I Serum, WB lysate NCEH 4y
1991–1994 Bio-Rad QP II Serum, WB lysate NCEH 4y
1999–2000 Bio-Rad QP II Serum, WB lysate NCEH 3y
2001–2002 Bio-Rad QP II Serum, WB lysate NCEH 3y
2003–2004 Bio-Rad QP II Serum, WB lysate NCEH 1y
2005–2006 Bio-Rad QP II Serum, WB lysate NCEH 1y
2007–2008 Microbiological Serum, WB lysate NCEH 1y
Microbiological Serum, WB lysate Trinity, UAB One-third subset, 1y
LC-MS/MS Serum, WB lysate NCEH One-third subset, 1y
2009–2010 Microbiological Serum, WB lysate NCEH 1y
LC-MS/MS Serum, WB lysate NCEH One-third subset, 1y
1 LC-MS/MS, liquid chromatography–tandem mass spectrometry; NCEH, Division of Laboratory Science, National Center for Environmental Health,
Centers for Disease Control and Prevention; Bio-Rad QP, Bio-Rad Quantaphase radio protein-binding assay (Bio-Rad Laboratories, Hercules, CA); Trinity,
Trinity College, Dublin, Ireland; UAB, University of Alabama at Birmingham, AL; WB, whole blood.
FOLATE-RELATED BIOMARKERS IN NHANES 305Sbetween laboratories were use of different folate calibrators and
a wild-type, compared with a chloramphenicol-resistant, Lac-
tobacillus rhamnosus microorganism.
Comparisons of MA with Bio-Rad results
As described in the background article by Yetley and Johnson
(1), meaningful time-trend analyses with the use of the NHANES
data require that method comparability be evaluated. When dif-
ferent measurement procedures produce different results, sta-
tistical or other types of adjustments are often needed so that
trends over time are reﬂective of real changes in nutritional status
and are not simply due to methodologic artifacts. Because of the
differences described above between the MA and Bio-Rad
results, the NCEH conducted crossover evaluations for serum
(31) and whole-blood folate (32) to assess the need for adjust-
ments between the NHANES-based Bio-Rad (1988–1994 and
1999–2006) and MA (2007–2010) results for time-trend evalu-
ations. The Bio-Rad results were, on average, 29% lower than the
MA results for serum (n = 325) and 45% lower for RBC folates
(n = 171). The roundtable agreed that the pronounced differ-
ences between the Bio-Rad and the MA necessitate data ad-
justments for time-trend analyses to make the results from the 2
procedures comparable (ie, as if they were done with the same
measurement procedure). Without such adjustments, it is unclear
what portion of time-trend differences are due to real changes in
folate status and what portion are due to differences in mea-
surement procedures.
Pfeiffer and Sempos presented several statistical models for
the adjustment of the transition between the Bio-Rad and MA
serum folate results. Each model gave a similar R
2 of ’0.95, but
the regression line to ﬁt the data varied between models (34).
The linear (least-squares) regression model is the simplest, but it
tends to overpredict at the tails of the serum folate distribution.
The piecewise linear regression model, as performed by Fazili
et al (31), requires predeﬁnition of the knot but provides better
estimates at the tails, which are important for the estimation of
at-risk groups’ prevalence. A more sophisticated approach for
a piecewise linear regression through a grid search that identiﬁes
the knot yields a very similar ﬁt, but has the advantage of no
break in the lines at the knot. Finally, the fractional polynomial
model best satisﬁes the statistical assumptions that underlie
these regression models and gives a slightly better ﬁt than the
other regression approaches. The roundtable noted that users
prefer the model that best ﬁts the data across the entire distri-
bution of serum folate concentrations, rather than the simplest
model.
ForRBCfolate,themethyltetrahydrofolatereductase(MTHFR)
C677T polymorphism affects folate vitamer distribution, and the
Bio-Rad results depend on the genotype (32, 35). The MA com-
pletelyrecoveredfolatesaddedtowhole-bloodhemolysatesexcept
for tetrahydrofolic acid (THF) (46%), whereas the Bio-Rad had
variable recoveries for several folate vitamers (Table 2). NCEH’s
Bio-Rad results were 48% lower than its MA results for samples
with the MTHFR 677 C/C and C/T genotypes and 31% lower for
samples with the T/T genotype. The Bio-Rad procedure’s geno-
type dependence complicates the derivation of a single adjustment
equation for NHANES data, which have no MTHFR genotype
information. In addition, MA measurements come from whole-
blood hemolysates. Calculations to convert results to RBC folate
concentrations require the addition and adjustment of a serum
folate value for the Bio-Rad–MA measurement procedure dif-
ferences. Information on the NCHS recommendation on how best
to deal with time-trend evaluations for RBC folate can be found
on the NHANES website (34).
The LC-MS/MS measurement procedure
TheroundtableconsideredtheuseofanLC-MS/MSprocedure
in future NHANES to measure total and individual folatevitamer
concentrations in serum and RBCs. The goal is to accurately
reﬂect the presence ofall intact biologicallyactivefolateforms in
vivo. Some folate species are more sensitive than others to ox-
idation and decomposition during sample processing and storage,
which results in interconversions and degradations that make
accurate measurement of individual species more of a challenge
than measurement of total folate concentrations. For total folate
estimates, accurately measured interconversions do not alter total
folate concentration results from summing across the individual
species (12, 36). However, individual folate species results do not
reﬂect in vivo patterns and quantities after interconversions and
degradations during processing and analysis.
Characteristics of the LC-MS/MS measurement procedure
The NCEH LC-MS/MS procedure measures 5MTHF (the
predominant folate species in serum and whole blood), FA, 5-
formyltetrahydrofolic acid (5FTHF), THF, and 5,10-methenyl-
tetrahydrofolic acid (31, 32, 37–39). The NCEH performance
characteristics for the LC-MS/MS procedure show good pre-
cision (CVs) for total folate and 5MTHF (Table 3). CVs are
higher for folate species, such as FA, present in lower concen-
trations. The NCEH procedure yields almost complete recovery
of all folate species with the use of the respective stable-isotope–
labeled internal standards. The LC-MS/MS procedure showed
consistent performance over several years, and always matched
the certiﬁed values for 5MTHF in the 3-level NIST SRM 1955
(Figure 1) and the assigned values for total folate, 5MTHF, FA,
and 5FTHF in the one-level NIBSC 03/178 reference material
(Figure 2).
TABLE 2
Fortiﬁcation and recovery results for the Bio-Rad Quantaphase II
measurement procedure and the microbiological assay
1
Bio-Rad Quantaphase II Microbiological assay
Folate species Serum WB Serum WB
5MTHF 61 6 95 1 6 48 8 6 99 7 6 11
FA 91 6 10 99 6 56 9 6 3—
5FTHF 38 6 14 18 6 0.1 120 6 9 124 6 7
5,10MethenylTHF 234 6 32 115 6 10 101 6 7 107 6 13
THF 106 6 27 152 6 19 36 6 10 46 6 8
1 All values are percentages 6 SDs. Serum results are from reference
31; recoveries of the microbiological assay and Bio-Rad Quantaphase II
(Bio-Rad Laboratories, Hercules, CA) methods were tested over 2 d by the
addition of each of the 5 folate calibrators (Merck Eprova; Merck & Cie,
Schaffhausen, Switzerland) at 10 nmol/L to a serum pool (21.8 nmol total
folate/L by liquid chromatography–tandem mass spectrometry). Whole-
blood (WB) results are from reference 32; recoveries were measured over
3 d. 5MTHF, 5-methyltetrahydrofolic acid; FA, folic acid; 5FTHF, 5-formylte-
trahydrofolic acid; 5,10MethenylTHF, 5,10-methenyltetrahydrofolic acid; THF,
tetrahydrofolic acid.
306S YETLEY ET ALFor serum, Pfeiffer described the results of an NCEH evalu-
ationofthereproducibilityoffolatespeciesconcentrationsacross
multiple measurements with the use of a one-third subsample
from NHANES 2007–2008. Pearson’s correlation coefﬁcients
were high for serum 5MTHF (r = 0.97, n = 1340), FA (r = 0.95,
n = 421), and 5FTHF (r = 0.90, n = 1338) between the ﬁrst and
repeat measurement. However, because of THF’s poor stability,
results showed no signiﬁcant correlation between the ﬁrst and
repeat measurement (r = 0.04). An assessment of the agreement
between the ﬁrst and repeat measurement with the use of Deming
regression analysis showed no proportional or constant bias for
serum 5MTHF (repeat measurement = 1.00 · ﬁrst measurement 2
0.36 nmol/L) and 5FTHF (repeat measurement = 1.02 · ﬁrst
measurement + 0.03 nmol/L), whereas serum FA showed a small
proportional and constant bias (log repeat measurement = 1.06 ·
log ﬁrst measurement 2 0.02 nmol/L; NCEH used log trans-
formation because of the distribution’s skewness).
The Joint Committee on Traceability in Laboratory Medicine
databaselists theNCEH isotope-dilutionMS/MSprocedureasan
accepted reference measurement procedure for the measurement
of serum 5MTHF, FA, and 5FTHF (40). Because the NCEH LC-
MS/MS–based results for serum 5MTHF and FAwere similar to
results from 3 LC-MS/MS procedures that NIST developed (41),
NIST included the NCEH results in the calculation of certiﬁed
values for 5MTHF and reference values for FA for SRM 1955
(28). The NCEH LC-MS/MS measurement procedure also
TABLE 3
Liquid chromatography–tandem mass spectrometry measurement performance characteristics of serum and red blood cell
folates
1
Compound Matrix Imprecision
2 Recovery
3,4 LOD
% % nmol/L
Total folate Serum 6–7 — —
5MTHF Serum 6–8 99 6 6.9 0.5
FA Serum 13–17 108 6 2.8 0.3
5FTHF Serum 9–19 101 6 1.9 0.1
Total folate WB lysate 4–7 — —
5MTHF WB lysate 5–6 92 6 1.8 0.5
FA WB lysate 13–19 90 6 3.8 0.3
THF WB lysate 17–29 101 6 19.7 1.0
5FTHF WB lysate 12–17 93 6 1.0 0.1
5,10MethenylTHF WB lysate 9–16 100 6 12.3 0.3
1 Serum was analyzed over 47 d for imprecision assessment; whole blood (WB) was analyzed over 25 d for impre-
cision assessment. LOD, limits of detection; 5MTHF, 5-methyltetrahydrofolic acid; FA, folic acid; 5FTHF, 5-formyltet-
rahydrofolic acid; 5,10MethenylTHF, 5,10-methenyltetrahydrofolic acid; THF, tetrahydrofolic acid.
2 Source: C Pfeiffer, personal communication, 2011.
3 Sources: reference 37 (for serum) and reference 38 (for WB lysate).
4 Values are mean percentages ± SDs.
FIGURE 1. Performance of the National Center for Environmental Health, Centers for Disease Control and Prevention, liquid chromatography-tandem
mass spectrometry measurement procedure over multiple years with the use of the National Institute of Standards and Technology standard reference material
(SRM) 1955 (28). Dotted lines represent the target concentrations for SRM levels 1, 2, and 3. Solid lines track the performance of the measurement procedure
for each SRM level between 2004 and 2010. 5MTHF, serum 5-methyltetrahydrofolate.
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with electrochemical detection procedure that Steven Bailey
of the University of Southern Alabama used [USAL = 0.99 ·
NCEH + 0.06 nmol/L, r = 0.00, n = 120 (CM Pfeiffer and SW
Bailey, personal communication, 2011)]. However, for RBC fo-
late, unresolved issues with the current LC-MS/MS measurement
procedure preclude its consideration as a reference method at this
time.
Comparison of LC-MS/MS and microbiological results for
serum and RBC total folates
For serum total folate, Pfeiffer reported that the NCEH LC-
MS/MS results were within 610% of the MA results in a study
(n = 325) of banked NHANES 1999–2004 samples (31) and
studies of 120 plasma samples from the University of Southern
Alabama Pharmacokinetics study and 48 proﬁciency testing
samples from the National External Quality Assessment Service.
The Pearson’s correlation coefﬁcients between the 2 measure-
ment procedures were all .0.98 for these studies. With the use
of a one-third subset of NHANES 2007–2008 data, the NCEH
obtained identical means, medians, minimum and maximum
values, and frequency distributions for the MA and LC-MS/MS
procedures. Deming regression analysis showed no proportional
or constant bias, with a correlation coefﬁcient of 0.95.
Pfeiffer reported that for whole-blood folates, the NCEH MA
results were 12% higher than the LC-MS/MS results for 171
samples from US and European blood banks (r = 0.94) (32) and
22% higher for 30 National External Quality Assessment Ser-
vice samples (r = 0.93). The MA produced 25% higher values
than the LC-MS/MS with NHANES 2007–2008 data (n = 295).
NCEH continues to investigate its whole-blood extraction pro-
cedure because residual amounts of diglutamyl folates may be
present in the incubated hemolysate. In addition, a slight loss of
THF might occur during the hemolysate incubation that the
presence of the internal standard does not compensate for.
The NCEH is also investigating the possibility that 4-a-
hydroxy-5MTHF (4hmTHF), an oxidation product of 5MTHF, is
generated during the preanalytic phase, hemolysate incubation,
or both (42, 43). The current NCEH LC-MS/MS procedure does
not separate 4hmTHF from 5FTHF. However, roundtable ex-
perts noted that 4hmTHF may be naturally present in serum.
Whether 4hmTHF occurs naturally or is a methodologic artifact
will determine whether to include it in the folate species sum-
mation to estimate total folate concentrations. The roundtable
suggested that a study measure compounds individually to de-
termine whether they generate other forms of folate.
The roundtable discussed other factors that may affect the
differences that the NCEH observed between the MA and LC-
MS/MS results for whole-blood folate. The oxygen in the he-
moglobin and thawing of stored samples can alter folate species
in whole-blood lysates. Because formylated folates are only
found in RBCs from individuals with the TT MTHFR genotype,
their presence in the RBCs of individuals with the CC genotype
likely indicates the production of artifacts during sample pro-
cessing or handling (44). Because of the pattern differences be-
tween folate species in the MTHFR C677T genotypes (32, 35),
a need exists for information on the comparability of MA and
LC-MS/MS results in other subgroups, such as alcohol or anti-
folate or anticonvulsant drug users and people with malabsorp-
tion problems.
Finally,theroundtablediscussedways topresent theLC-MS/MS
results. For total folate concentrations, interconversions between
different forms are not a concern as long as they stay intact, retain
their biological activity, and are measurable with equal efﬁciency
(12). However, quantitative data on the individual species must
accurately reﬂect what was in the original sample. For example,
because of the pH that the NCEH procedure used, interconver-
sions between 10FTHF, 5,10-methenyl-tetrahydrofolic acid, and
5FTHF occur. The SRM 1955 and NHANES 1999–2002
have produced quantitative values only for serum 5MTHF and
FA. When LC-MS/MS is used, NCEH estimates total folate
FIGURE 2. Performance of the National Center for Environmental Health, Centers for Disease Control and Prevention, liquid chromatography–tandem
mass spectrometry measurement procedure over multiple years with the use of the National Institute for Biological Standards and Control reference material
03/178 (29). Dotted lines represent the target concentrations for total folate, 5-methyltetrahydrofolate (5MTHF), folic acid (FA), and 5-formyltetrahydrofolic
acid (5FTHF) in this reference material. Solid lines track the performance of the measurement procedure for each folate species and the total folate between
2005 and 2010 (CM Pfeiffer, unpublished observations, 2011).
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ylated and nonmethylated folates.
Roundtable statisticians agreed that potential errors associated
withsummingacrossmultiplespeciestoobtaintotalfolatevalues
should not affect total means but could increase variances. For
NHANES serum folate data, the 5MTHF that represents most
folate in serum has a small CV, which results in a small CV (ie,
imprecision) for total folate estimates (Table 3).
Measurement of folate vitamers in surplus serum from
NHANES
Jacob Selhub discussed the measurement of serum 5MTHF
and FA with the use of afﬁnity/HPLC in surplus serum from
NHANES 1999–2002 at Tufts University (Table 4) (10, 15, 45–
47). With the use of the NHANES 2001–2002 data that Tufts
University generated, Regan Bailey (8) provided folate vitamer
results for an analytic sample of .1100 persons aged 60 y
who had fasted; 38% had a detectable serum FA concentration.
Although the trend for elevated serum FA concentrations with
increased FA intakes was signiﬁcant, this relation varied. Some
people with low FA intakes had detectable serum FA concen-
trations. Morris et al (10), with the use of the same NHANES
data, reported that in persons with low vitamin B-12 status (ie,
serum vitamin B-12 , 148 pmol/L or plasma methylmalonic
acid . 210 nmol/L), the presence of detectable circulating FA
concentrations was related to lower cognitive test scores and
lower mean cell volumes.
The roundtable agreed that the data on folate species are use-
ful for the study of polymorphisms and their disease risks, but
NHANES lacks MTHFR and other genotype information. Several
experts suggested that, without genotype information, NHANES
researchers use RBC patterns of folate species, if available, as
a surrogate indicator of MTHFR C677T polymorphism status (38).
However, inconsistencies in patterns from 2 laboratories (38, 44)
underscore the need for accurate folate species measurement for
this approach. Furthermore, the presence of circulating FA, asso-
ciated with FA fortiﬁcation and the increasing use of FA-fortiﬁed
foods and supplements, might adversely affect cancer risk and
vitamin B-12 status (18, 19, 48). The roundtable noted the current
paucity of information on the metabolism and functional effects of
serum FA, such as the degree to which free FA correlates with
circulating folate-binding proteins; whether the body endogenously
produces FA and, if so, by what mechanism; what effect poly-
morphisms have; and how long FA remains in circulation.
NIST REFERENCE MEASUREMENT PROCEDURES AND
MATERIALS FOR SERUM FOLATES
Karen Phinney reported that the NIST SRM 1955 for folate in
human serum contains 3 reference materials: level 2 is unaltered
human serum, level 1 is diluted with phosphate-buffered saline
because of the difﬁculty of obtaining low levels of some folate
species, and level 3 is fortiﬁed with 5MTHF (28, 41). SRM 1955
has certiﬁed values for 5MTHF, reference values for FA, and
information values for total folate and 5FTHF.
NIST developed several LC-MS/MS procedures to assign
values for serum folate species in SRM 1955 for homocysteine
and folate in human serum; these are described in detail else-
where (28, 41, 49–51). The Joint Committee on Traceability in
Laboratory Medicine database lists these as approved reference
measurement procedures for serum 5MTHF and FA (40). NIST
assigned values for the SRM 1955 folate species based on an-
alyses from both NIST and NCEH (28).
The NIST is developing SRM 1950, its ﬁrst plasma-based
reference material for use by the metabolomics community to
measure metabolites (52). The NIST is not developing this SRM
speciﬁcally for folate but will provide a certiﬁed value for
5MTHF and a reference value for FA. SRM 1950 is a human
plasma pool from 100 donors (equal numbers of men and
women aged 40–50 y). The NIST and NCEH are characterizing
the SRM 1950 values with the use of LC-MS/MS.
The NIST will revisit some of its methodologies for the
quantiﬁcation of folate vitamers, for example, to increase pre-
cision at low vitamer concentrations and agreement between
measurement procedures (eg, FA), and to quantify additional
vitamers. The NISTwill evaluate potential interferences and will
determine whether some measured vitamers are in vivo species or
artifacts of sample handling. The NISTwill also develop a certiﬁed
value for total folate. The NIST does not have a measurement
procedure for RBC folate, which precludes the development of
reference materials for RBC folate at this time.
The roundtable noted the difﬁculties in the identiﬁcation of the
measurand ormeasurandsand theneed foracommutability study
to determine whether the reference material behaves similarly to
TABLE 4
Measurement of serum 5-methyltetrahydrofolate and folic acid in NHANES
1
Survey Assay Matrix Laboratory Population age
1974–1975 — — — —
1976–1980 — — — —
1988–1994 — — — —
1999–2000 Afﬁnity/HPLC Surplus sera Tufts
2 60 y
2001–2002 Afﬁnity/HPLC Surplus sera Tufts
2 60 y
2003–2004 — — — —
2005–2006 — — — —
2007–2008 LC-MS/MS Serum, RBC NCEH One-third subset, 1y
2009–2010 LC-MS/MS Serum, RBC NCEH One-third subset, 1y
1 LC-MS/MS, liquid chromatography–tandem mass spectrometry; RBC, red blood cell; NCEH, National Center for
Environmental Health, Centers for Disease Control and Prevention.
2 Jean Mayer USDA Human Nutrition Research Laboratory, Tufts University, Boston, MA. Measurement procedure:
afﬁnity/HPLC with electrochemical detection.
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SRM 1955 should work reasonably well for the level 2 material
because it is unaltered serum, but commutability may be an issue
for levels 1 (derived from diluted materials) and 3 (a fortiﬁed
material). Therefore, the value of the SRM 1955 materials as
a reference material and trueness control for levels 1 and 3 is not
currently clear.
ROUNDTABLE DIALOGUE
Measurement procedures for future NHANES
Forserumfolate,theroundtablegenerallyagreedthatNHANES
should use the LC-MS/MS procedure in the future because of the
identical results between the MA and the LC-MS/MS procedure
and the increasing interest in the measurement of individual folate
forms that the LC-MS/MS procedure, but not the MA, can detect.
As a chemical measurement procedure, the LC-MS/MS is a
metrologically higher-order procedure than the MA, which is a
biological procedure. LC-MS/MS can also provide valuable
information that other measurement procedures cannot (eg, in-
dividual folate species and the accumulation of byproducts). The
NCEH is planning a round robin for serum folate with 2–3
laboratories, similar to the 3-laboratory comparison study for
MA. The experts wondered whether, given the procedure’s dy-
namic range, dilutions are necessary for good precision in the
fortiﬁed US population. Pfeiffer noted that the calibration range
for LC-MS/MS is 1–100 nmol/L for 5MTHF and 0.5–50 nmol/L
for minor folate species, and linearity goes beyond even the
calibration range. Only a few samples exceed the calibration
range and require dilution.
For RBC folates, the roundtable experts agreed that the use of
the LC-MS/MS procedure is premature because results with the
LC-MS/MS and MA procedures in the NCEH laboratory differed
by 20–25%. Research must identify the source of these differ-
ences. In addition, no reference materials are available for RBC
folates. Therefore, for RBC folates, the roundtable agreed that
MA is currently the preferred measurement procedure.
Which biomarkers?
The roundtable discussed whether future NHANES should
continue to measure serum and RBC folate biomarkers given that
public health concerns have shifted to the safety of high FA
intakes and the potential for adverse effects from long-term
exposures to FA in serum (also referred to as unmetabolized FA)
after fortiﬁcation.
The roundtable considered whether both serum and RBC
folate measures are necessary to monitor folate concentrations
in the US population. Experts had regarded RBC folate concen-
trations as better folate status measures because they are inte-
grative measures of folate intakes over RBC’s 90–120-d lifespan,
whereas serum folate concentrations reﬂect recent intakes. The
higher folate concentrations in RBC compared with serum also
made RBC measurements easier. However, these factors may no
longer be relevant to NHANES. The general population does not
change daily intakes drastically, and current procedures can
measure serum folate concentrations accurately. Therefore, RBC
folate concentrations might not be more useful than serum folate
concentrations for NHANES.
The roundtable agreed that serum or RBC folate would be
useful in the assessment of folate status in NHANES, and noted
that serum folate’s advantages include its wide use in clinical
settings. RBC folate falls with vitamin B-12 deﬁciency (and
probably would not rise as high in folate-supplemented subjects
with signiﬁcant vitamin B-12 deﬁciency as it would in those
without vitamin B-12 deﬁciency), which makes it useful in the
evaluation of folate’s effects on vitamin B-12–deﬁcient subjects.
However, the rationale for the selection of a folate-related bio-
marker for a large survey might not apply to clinical settings.
RBC folate measures remain useful in clinical settings because
recent intake changes with a disease or acute illness affect them
less than they do serum folate concentrations. Therefore, RBC
folate concentrations give a more accurate picture than do serum
folate concentrations of patients’ underlying folate status.
Additional NHANES data analyses could provide information
on the usefulness of single, compared with combination, folate
status measures. Our incomplete knowledge of what serum and
RBC folate concentrations actually reﬂect hampers the decision
about which biomarker is preferable. Forexample,the magnitude
of serum and RBC folate concentration responses to FA forti-
ﬁcation in the United States showed marked differences (119–
161% increase for serum, 44–64% increase for RBC) (5), and the
RBC folate concentrations did not show the expected plateau
effect if tissue saturation occurs at higher intakes (53). Monitoring
serum and RBC folates could produce new information, particu-
larly if NHANES uses LC-MS/MS procedures. Measurement of
FA in serum could shed light on the prevalence of at-risk pop-
ulation groups and correlates of risk (8, 10, 54). Folate-related
polymorphisms are more likely to relate to RBC than are serum
folateconcentrations, particularlytothe patternoffolatespeciesin
RBC (32, 38).
SUMMARY
A roundtable evaluated the use of folate status biomarkers in
past, current, and future NHANES. They evaluated the public
health merits of the inclusion of these measures in NHANES, the
quality of measurement procedures that past NHANES haveused
or are available for future NHANES, and the quality of the ref-
erence measurement procedures and materials available or under
development. They noted a systematic bias in the Bio-Rad results
that NHANES 1991–1994 and 1999–2006 used as compared with
the MA and LC-MS/MS measurement procedures used in
NHANES 2007–2010. Comparison of Bio-Rad results with the
NHANES 2007–2010 MA-based results will require statistical
adjustments if time trends are to be evaluated. The roundtable also
supported the use of the LC-MS/MS procedure for the measure-
ment of serum folate in future NHANES but agreed that this
procedure is not yet fully validated for the measurement of RBC
folates.
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